Drug Approval | August 16, 2022
Lupin receives approval from U.S. FDA for Meclizine Hydrochloride Tablets USP
Meclizine Hydrochloride Tablets had estimated annual sales of USD 29 million in the U.S.
Meclizine Hydrochloride Tablets had estimated annual sales of USD 29 million in the U.S.
The approved product has an estimated market size of around US$ 606 million for the twelve months ending June 2022, according to IQVIA.
Quetiapine Extended-Release Tablets are indicated for the treatment of Schizophrenia, Bipolar disorder and adjunctive treatment of Major Depressive Disorder (MDD)
Man lost 54 Kgs in 6 months with MGB procedure
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
Donor privilege cards given to the families of all the donors from across Karnataka as a token of appreciation
The company has reported total income of Rs. 403.38 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 65.19 crores during the period ended June 30, 2022.
Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions
Subscribe To Our Newsletter & Stay Updated
